All In Biotech

Drug Trial Radar · NCT01709318

A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012)

A Multicenter, Randomized, Partially-blinded, Phase IIb Dose-finding Study on Ovarian Function, Vaginal Bleeding Pattern, and Pharmacokinetics Associated With the Use of Combined Vaginal Rings Releasing 17β-estradiol Plus Three Different Doses of Either Nomegestrol Acetate or Etonogestrel in Healthy Women Aged 18-35 Years. Protocol MK-8175A/MK-8342B 012

Last checked: Nov 20, 2026Latest source record: May 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 666 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

666

Actual

Start

Dec 12, 2012

Primary completion

Oct 22, 2013

Study completion Oct 22, 2013

Sponsor

Lead sponsor
Organon and CoIndustry
Sponsor type
Industry
First posted
Oct 18, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
Female only, from 18 years, up to 35 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this trial was to identify at least one next generation ring (NGR) that demonstrates inhibition of ovulation (which was considered confirmed if in the subset of participants ovulation was observed in less than 15% of the participants at any time during the 3 treatment cycles of the study) and cycle control that was non-inferior to NuvaRing®, as judged by the incidence of breakthrough bleeding and/or spotting (BTB-S) during Cycle 3. The primary hypothesis was that at least 1 of the 6 NGRs would show inhibition of ovulation and cycle control during Treatment Cycle 3 that is non-inferior to NuvaRing®, as judged by the incidence of BTB-S.

Conditions

  • Contraception

Interventions

  • Nomegestrol acetate (NOMAC)Drug

    Daily release of 500, 700, or 900 μg.

  • Etonogestrel (ENG)Drug

    Daily release of 75, 100, 120 or 125 μg

  • Ethinyl estradiol (EE)Drug

    Daily release of 15 μg

  • Estradiol (E2)Drug

    Daily release of 300 μg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Ovulation Incidence, by CycleTime frame: Day 1 of Treatment Cycle 1 through Day 28 of Treatment Cycle 3 (Up to ~92 days)
  2. Percentage of Participants With Progesterone Concentrations >16 Nmol/L, by CycleTime frame: Day 1 of Treatment Cycle 1 through Day 28 of Treatment Cycle 3 (Up to ~92 days)
  3. Percentage of Participants With Breakthrough Bleeding and/or Spotting During Cycle 3Time frame: Day 1 Cycle 3 through Day 28 Cycle 3 (Up to ~28 days)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.